{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:25:12Z","timestamp":1791483912026,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/icu.0b013e32833f1060","type":"journal-article","created":{"date-parts":[[2010,9,14]],"date-time":"2010-09-14T07:17:22Z","timestamp":1284448642000},"page":"463-467","source":"Crossref","is-referenced-by-count":23,"title":["An update on the cause and treatment of scleritis"],"prefix":"10.1097","volume":"21","author":[{"given":"Aleksandra","family":"Rachitskaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrem D","family":"Mandelcorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Albini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210206","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R2-10-20210206","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.iio.0000155900.64809.b2","article-title":"The diagnosis and management of anterior scleritis","volume":"45","author":"Albini","year":"2005","journal-title":"Int Ophthalmol Clin"},{"key":"R3-10-20210206","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0161-6420(95)30970-0","article-title":"Scleritis associated with systemic vasculitic diseases","volume":"102","author":"Sainz de la Maza","year":"1995","journal-title":"Ophthalmology"},{"key":"R4-10-20210206","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajo.2009.07.021","article-title":"Scleritis and systemic disease association in a community-based referral practice","volume":"148","author":"Raiji","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R5-10-20210206","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med"},{"key":"R6-10-20210206","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.4076\/1757-1626-2-8148","article-title":"Amitriptyline for pain control in scleritis may help to avoid excessive steroid use in selected cases: a case report","volume":"2","author":"Ohn","year":"2009","journal-title":"Cases J"},{"key":"R7-10-20210206","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9394(00)00710-8","article-title":"Episcleritis and scleritis: clinical features and treatment results","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R8-10-20210206","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) cohort study","volume":"15","author":"Kempen","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"key":"R9-10-20210206","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"R10-10-20210206","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R12-10-20210206","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Kacmaz","year":"2010","journal-title":"Ophthalmology"},{"key":"R13-10-20210206","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"key":"R14-10-20210206","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3129\/i09-061","article-title":"Infliximab for the treatment of active scleritis","volume":"44","author":"Sen","year":"2009","journal-title":"Can J Ophthalmol"},{"key":"R15-10-20210206","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bjo.2008.150961","article-title":"Infliximab for the treatment of refractory scleritis.","volume":"94","author":"Doctor","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R16-10-20210206","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s10384-008-0652-5","article-title":"Treating refractory scleritis with infliximab","volume":"53","author":"Ahn","year":"2009","journal-title":"Jpn J Ophthalmol"},{"key":"R17-10-20210206","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/j.1755-3768.2009.01546.x","article-title":"Regression of necrotizing scleritis in Wegeners granulomatosis after infliximab treatment.","volume":"88","author":"Kontkanen","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R18-10-20210206","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10067-009-1368-8","article-title":"Successful treatment of severe nodular scleritis with adalimumab","volume":"29","author":"Restrepo","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R19-10-20210206","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R20-10-20210206","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/bjo.2007.126425","article-title":"Immunopathology of necrotising scleritis","volume":"92","author":"Usui","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R21-10-20210206","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/bjo.2007.133173","article-title":"Rituximab for treatment of ocular inflammatory disease: a series of four cases","volume":"93","author":"Kurz","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R22-10-20210206","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/bjo.2008.147157","article-title":"Rituximab for treatment of scleritis associated with rheumatoid arthritis","volume":"93","author":"Chauhan","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R23-10-20210206","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R24-10-20210206","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.ophtha.2005.05.008","article-title":"Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis","volume":"112","author":"Albini","year":"2005","journal-title":"Ophthalmology"},{"key":"R27-10-20210206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2009.07.035","article-title":"Evaluation of sub-tenon triamcinolone acetonide injections in the treatment of scleritis","volume":"149","author":"Johnson","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R28-10-20210206","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.survophthal.2005.04.001","article-title":"Scleritis","volume":"50","author":"Okhravi","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R29-10-20210206","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.eye.6703099","article-title":"Microbial scleritis-experience from a developing country","volume":"23","author":"Jain","year":"2009","journal-title":"Eye (Lond)"},{"key":"R30-10-20210206","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/09273940802140804","article-title":"Nocardia asteroides necrotizing scleritis associated with subtenon triamcinolone acetonide injection","volume":"16","author":"Seth","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"R31-10-20210206","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ajo.2009.06.025","article-title":"Chronic herpes simplex scleritis: characterization of 9 cases of an under-recognized clinical entity","volume":"148","author":"Bhat","year":"2009","journal-title":"Am J Ophthalmol"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICU.0b013e32833f1060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:32:40Z","timestamp":1786041160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00055735-201011000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0b013e32833f1060","relation":{},"ISSN":["1040-8738"],"issn-type":[{"value":"1040-8738","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}